Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

Cangrelor for ACS—lessons from the CHAMPION trials

Nature Reviews Cardiology volume 7, pages 124–125 (2010)Cite this article

Subjects

A Correction to this article was published on 01 May 2010

The two CHAMPION trials failed to show superiority of cangrelor (a rapid-acting, reversible intravenous platelet P2Y12 adenosine receptor antagonist) versus clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. The CHAMPION PCI trial, however, did show a significant reduction in death and stent thrombosis suggesting benefit in those without clopidogrel pretreatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The CHAMPION trials reaffirm that pretreatment with a P2Y12 antagonist is superior to delaying treatment until after the PCI procedure.

References

  1. Harrington, R. A. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361, 2318–2329 (2009).

    Article  CAS  Google Scholar 

  2. Bhatt, D. L. et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330–2341 (2009).

    Article  CAS  Google Scholar 

  3. Mehta, S. CURRENT OASIS 7: A 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patient with ACS undergoing an early invasive strategy with intent for PCI. Presented at the ESC Congress, 29 August–2 September 2009; Barcelona, Spain.

  4. Akers, W. S. et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J. Clin. Pharmacol. doi:10.1177/0091270009344986.

    Article  CAS  Google Scholar 

  5. Prasad, A. et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol. 54, 477–486 (2009).

    Article  Google Scholar 

  6. Steinhubl, S. R. et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121, 527–534 (2008).

    Article  CAS  Google Scholar 

  7. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).

    Article  CAS  Google Scholar 

  8. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 36 1, 1045–1057 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street, BC3-012P, Boston, 02120, MA, USA

    David P. Faxon

Authors
  1. David P. Faxon
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faxon, D. Cangrelor for ACS—lessons from the CHAMPION trials. Nat Rev Cardiol 7, 124–125 (2010). https://doi.org/10.1038/nrcardio.2009.247

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.247

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing